Results 261 to 270 of about 2,872,365 (306)

Rapid intravenous symptom-inhibiting fentanyl induction (SIFI) to optimize rotation onto oral opioid agonist therapy among individuals who use unregulated fentanyl: protocol for an open-label, single arm clinical trial. [PDF]

Addict Sci Clin Pract
Azar P, Ignaszewski MJ, Harris M, Barazanci Z, Davison R, Wong JSH, Maharaj A, Mathew N, Hall D, Guillemi SA, Foreman J, Barrios R, Montaner JSG.   +12 more
europepmc   +1 more source

Opioid withdrawal syndrome‐associated cognitive impairment: A narrative review

The American Journal on Addictions, Volume 35, Issue 6, Page 661-672, November 2026.
Abstract Background and Objectives Opioid withdrawal syndrome (OWS) comprises a transient constellation of subjective symptoms and objective signs expressed by brain and other organs. Although cognitive impairment is well documented in opioid use and addiction, little is known about cognitive impairment that may specifically accompany OWS.
Faizan Khan, Nazli Tunali, R. Andrew Chambers   +2 more
wiley   +1 more source

Measuring sustainability of opioid agonist therapy programs in the context of transition from global fund support. [PDF]

Harm Reduct J
Stuikyte R, Varentsov I, Cook C, Dvoriak S.   +3 more
europepmc   +1 more source

Meta‐Analysis: The Placebo Response in Modern Treatments for Cholestatic Pruritus: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 10, Page 1348-1361, November 2026.
Placebo arms show substantial improvement in cholestatic pruritus, with up to 30% response rate. Estimates differed across outcome instruments, highlighting the importance of endpoint selection and realistic placebo assumptions in future trial design.
Igor Boechat Silveira, Leonardo Corrêa Süffert, Gustavo André Pedral Diniz Leite, Milena Ramos Tomé, Sarah Quick Lourenço de Lima, Gabriel André Pedral Diniz Leite, Bernardo de Faria Moraes, Pedro Robson Costa Passos, Guilherme Grossi Lopes Cançado   +8 more
wiley   +1 more source

The Impact of Heterogeneity in Individual Characteristics and Motivation to Quit Heroin Use on Contingency Management and Opioid Agonist Treatment Response: A Latent Class Analysis

Drug and Alcohol Review, Volume 45, Issue 7, November 2026.
ABSTRACT Introduction Contingency Management (CM) involves the systematic application of positive reinforcement (financial incentives) to promote behaviour change, to improve treatment outcomes for individuals with opioid use disorder (OUD). To better understand patient heterogeneity, this study sought to identify meaningful subgroups/classes ...
Louise MacGregor, Timothy Weaver, John Strang, Stephen Pilling, Nicola Metrebian, Kimberley Goldsmith   +5 more
wiley   +1 more source

Sustainability of opioid agonist therapy programmes in Belarus, the Republic of Moldova, Tajikistan and Ukraine in the context of transition from Global Fund support during 2020-2023. [PDF]

Harm Reduct J
Stuikyte R, Varentsov I, Malikov N, Dvoriak S, Filippovych M, Latypov A, Kralko A, Iatco A, Cook C.   +8 more
europepmc   +1 more source

Correction: Measuring sustainability of opioid agonist therapy programs in the context of transition from Global Fund Support. [PDF]

Harm Reduct J
Stuikyte R, Varentsov I, Cook C, Dvoriak S.   +3 more
europepmc   +1 more source

The silent consequence of overdose: The case for brain injury‐informed opioid treatment

Addiction, Volume 121, Issue 11, Page 3142-3144, November 2026.
Nathaniel Day, Kym Kaufmann, Mauricio Garcia‐Barrera, Jitender Sareen, Daniel Vigo   +4 more
wiley   +1 more source